Japan Tissue Engineering Co., Ltd. (TYO:7774)

Market Cap	25.10B +51.1%
Revenue (ttm)	2.18B -11.1%
Net Income	-734.00M
EPS	-18.07
Shares Out	40.61M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	158,500
Average Volume	146,435
Open	598.00
Previous Close	593.00
Day's Range	589.00 - 624.00
52-Week Range	448.00 - 883.00
Beta	0.58
RSI	53.56
Earnings Date	May 1, 2026

About Japan Tissue Engineering

Japan Tissue Engineering Co., Ltd. engages in the regenerative medicine business in Japan. The company operates through Regenerative Medicine Product, Regenerative Medicine Contract, and Research and Development Support segments. It offers autologous cultured epidermis, cartilage, corneal epithelium, and oral mucosal epithelium to medical institutions for the purpose of medical treatment. The company also provides tissue-engineered medical products. In addition, it researches and develops human 3-dimensional cultured tissue models for use in th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 204
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 7774

Financial Performance

In fiscal year 2026, Japan Tissue Engineering's revenue was 2.18 billion, a decrease of -11.12% compared to the previous year's 2.46 billion. Losses were -734.00 million, 187.8% more than in 2025.